Cintas Corporation vs Cytokinetics Inc — how do they compare? Cintas Corporation trades at $205.28 (market cap $82.15B), while Cytokinetics Inc trades at $77.39 (market cap $10.63B). The key difference: Cintas Corporation is far larger — about 7.7× Cytokinetics Inc's market cap, and Cintas Corporation pays a 1.01% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CTAS | CYTK | |
|---|---|---|
Market Cap | $82.15B | $10.63B |
Sector | Industrials | Technology |
52-Week High | $225.10 | $87.26 |
52-Week Low | $163.55 | $34.31 |
Enterprise Value | $84.56B | $10.74B |
Dividend Yield | 1.01% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Trailing returns across standard periods
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →